Merck KGaA, Darmstadt, Germany × Valo Health, Inc.
Merck KGaA entered a strategic collaboration with Valo Health to use Valo's AI drug discovery platform for Parkinson's disease. [44] The deal gives Merck access to insights from Valo's platform, which analyzes over 17 million de-identified patient records and biobank samples. [44, 47] The total potential value of the deal, including an upfront payment, R&D funding, and future success-based milestones, is over $3 billion. [44, 47, 53, 54]
The asset
A multi-year licensing collaboration for Valo's AI-enabled human causal biology platform to discover and develop novel treatments for Parkinson's disease and related disorders.
- 17M de-identified patient records
The record
- Seller status
- Going concern
- Sector
- AI drug discovery
- Modalities
- text, biomarkers
- Jurisdiction
- US
- Personal data
- de-identified
What it means if you hold data
This is one of the largest AI-drug-discovery deals in neurology, highlighting big pharma's increasing reliance on licensing large-scale, longitudinal real-world patient data and AI platforms to de-risk and accelerate their R&D pipelines for complex diseases. [47]